SurgiLight seeks US trial for presbyopia laser:
This article was originally published in Clinica
Executive Summary
SurgiLight has filed an application with the US FDA to start a multicentre, 350-patient trial of it laser treatment for presbyopia, a vision problem believed to affect around 90 million people in the US over the age of 40. Data from four sites outside the US have shown that the company's OptiVision system reversed presbyopia in nine of every 10 eyes of more than 100 eyes treated, with the results extending up to one year after surgery, says Orlando, Florida-based SurgiLight.